- The presentations were held during the annual American Society of Mass Spectrometry conference – an event attended by more than 10,000 scientists
- Research focused on a wide range of applications ranging from cancer research to biomarker discovery
- The number of PCT-related presentations during the 2019 conference exceeded prior Pressure BioSciences records for a scientific meeting, demonstrating the platform’s broad applicability potential
Pressure BioSciences Inc.’s (OTCQB: PBIO) patented pressure cycling technology (PCT) platform was featured prominently in 15 independent scientific presentations delivered during the annual conference of the American Society of Mass Spectrometry (ASMS) that took place June 1-6, 2019 in Atlanta, Georgia, as the company announced in a recent press release (http://ibn.fm/vLiCW).
The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953.
This year’s PCT-involving presentations spanned a range of applications – from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO’s PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences’ Barocycler 2320EXT instrument and its associated and proprietary MicroTubes.
Data suggest that the use of the PCT platform accelerates and strengthens protein analysis, improving cancer characterization and providing clinically relevant information at the end of the trial.
Researchers from both Australia and China reported advances in their cancer diagnostic programs. These programs are reliant on the PBIO PCT platform for the rapid extraction of proteins from tumor tissues for the purpose of analysis and treatment guidance.
Pressure BioSciences PCT platform was also used in studies aiming to provide more clarity on the racial disparities in cancer. Through such studies, medical professionals could eventually start offering better early screening and detection opportunities among minority groups.
A few other presentations focused on cancer biomarker discovery and protein/molecular biology research.
“The number of PCT-related presentations at the 2019 ASMS conference significantly exceeded prior PBI records for a scientific meeting. We are gratified that the use of our PCT platform continues to expand to new investigators and laboratories worldwide, and that its use has shown great promise in critical areas of human health, such as cancer,” Pressure BioSciences Global Director of Sales and Marketing Roxanna McCloskey said in a news release.
Being featured during presentations at such a prestigious scientific event shows the increasing potential of the PCT technology in diagnostics and discovery, according to McCloskey. The Pressure BioSciences team believes that such platforms could eventually be utilized routinely in precision medicine, a field that’s expanding rapidly and is anticipated to reach a volume of $216.75 billion by 2028, according to BIS Research (http://ibn.fm/FbaSz).
Pressure BioSciences is a leader in the development of innovative pressure-based solutions for the global life sciences industry. The company’s products are based on the properties of static and alternating hydrostatic pressure. PCT is a patented technology platform that uses alternating cycles of hydrostatic pressure to control bio-molecular interactions. Pressure BioSciences’ primary goal for the platform is the development of PCT-based products for biomarker discovery, drug development, biotherapeutics, forensics and soil and plant biology, to name but a few areas of focus and interest.
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
